Showing results (21-30 of 52) with videos related to
Sort By:
Pageof 6
Biorxiv : the Preprint Server for Biology|September 2, 2020
A simplified cell-based assay to identify coronavirus 3CL protease inhibitorsSamuel J Resnick, Sho Iketani, Seo Jung Hong, et al.Emerging Microbes & Infections|November 27, 2021
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesPengfei Wang, Ryan G Casner, Manoj S Nair, et al.Biorxiv : the Preprint Server for Biology|October 21, 2021
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesPengfei Wang, Ryan G Casner, Manoj S Nair, et al.Emerging Microbes & Infections|September 15, 2020
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe diseasePengfei Wang, Lihong Liu, Manoj S Nair, et al.Nature|October 23, 2023
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spikeQian Wang, Yicheng Guo, Liyuan Liu, et al.Journal of Virology|April 29, 2021
Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated CytotoxicitySamuel J Resnick, Sho Iketani, Seo Jung Hong, et al.Science Translational Medicine|May 24, 2023
A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivoClare Burn Aschner, Krithika Muthuraman, Iga Kucharska, et al.Nature|July 5, 2022
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5Qian Wang, Yicheng Guo, Sho Iketani, et al.Nature|March 8, 2021
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7Pengfei Wang, Manoj S Nair, Lihong Liu, et al.Nature Communications|July 4, 2023
An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivoMoriya Tsuji, Manoj S Nair, Kazuya Masuda, et al.Pageof 6